Experienced in Otitis Media with Effusion

Naomi Kiyota

Kobe, JP 
Experienced in Otitis Media with Effusion
Kobe, JP 
OverviewLocationsClinical Research

Overview

Naomi Kiyota practices in Kobe, Japan. Ms. Kiyota is rated as an Experienced expert by MediFind in the treatment of Otitis Media with Effusion. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Thyroid Cancer, Salivary Gland Tumors, Glossectomy, and Thyroidectomy.

Her clinical research consists of co-authoring 186 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Otitis Media with Effusion.

Gender
Female

Locations

Kobe, Japan
Other Locations
Chuo, Japan
Department Of Head And Neck Surgery, Japan
Division Of Head And Neck Medical Oncology, 6-5-1 Kashiwanoha, Kashiwa, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab, Fluorouracil, Cisplatin, Carboplatin
Study Phase: Phase 3
View 1 Less Clinical Trial

186 Total Publications

Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kiyota's expertise for a condition
ConditionClose
View All 40 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile